Developing gene therapy technology for retinitis pigmentosa
Employees: 1-10
Founded date: 2016
Investors 3
| Date | Name | Website |
| 08.02.2022 | Real Tech ... | en.realtec... |
| - | JIC Ventur... | j-vgi.co.j... |
| 08.12.2024 | Spiral Cap... | spiral-cap... |
Mentions in press and media 4
| Date | Title | Description |
| 01.05.2026 | Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy | Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit. No dose-limit... |
| 13.02.2025 | Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa | The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients. TOKYO, Feb. 13, 2025 /PRNewswir... |
| 04.03.2022 | This Startup Ecosystem In Japan Is Powering Medical Innovation | Imagine being able to reverse vision loss with a single injection. A Japanese startup is working on a simple gene therapy that would improve the quality of life for thousands of people with retinitis pigmentosa, a disease that causes blindn... |
| - | Restore Vision | “Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.” |